Ironwood Pharmaceuticals IRWD Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Ironwood Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ironwood Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ironwood Pharmaceuticals's stock-based comp?
- Ironwood Pharmaceuticals (IRWD) reported stock-based comp of $3.65M in Q1 2026.
- How has Ironwood Pharmaceuticals's stock-based comp changed year-over-year?
- Ironwood Pharmaceuticals's stock-based comp decreased by 31.0% year-over-year, from $5.29M to $3.65M.
- What is the long-term trend for Ironwood Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Ironwood Pharmaceuticals's stock-based comp has grown at a -6.2% compound annual growth rate (CAGR), from $22.28M to $17.25M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.